Cancer Drug Update (US): Celcuity’s REVTORPYK (gedatolisib) won FDA approval for HR+/HER2−, locally advanced or metastatic breast cancer without a detected PIK3CA mutation, to be used with fulvestrant (with or without palbociclib) after progression on endocrine therapy; commercialization is planned for late Q3 2026, with a supplemental filing for PIK3CA-mutant disease in Q3 2026. Public Health—Measles (US): CDC data show a historic measles surge, with 2,318 cases reported nationwide—highest since 1991—spreading across age groups as vaccination rates continue to slip. Infectious Disease—Ebola (DR Congo): Escalating conflict in eastern DR Congo is hampering Ebola containment, with reports of over 1,000 confirmed deaths and major mental-health fallout for children. Health Systems & Workforce (UK): The Royal College of Physicians says resident doctors remain at high burnout risk and highlights training environment concerns, as it is shortlisted for a lobbying award tied to its next-generation campaign. Policy & Access (Wisconsin, US): Gov. Tony Evers announced Wisconsin ranked in the top five for veteran employment services for the third straight year, ahead of National Hire a Veteran Day. Global Health & Nutrition: Scientists warn climate change is likely to reduce key nutrients in staple foods, raising the stakes for nutrition security. Pharma Safety (UAE): Emirates Drug Establishment says it’s stepping up inspections of compounding pharmacies and reports no unapproved peptide products found in licensed warehouses.